Abbott Reports (ILUMIEN IV) OPTIMAL PCI Clinical Trial Results of OCT Intravascular Imaging

Share this

Abbott Reports (ILUMIEN IV) OPTIMAL PCI Clinical Trial Results of OCT Intravascular Imaging


  • The results from the (ILUMIEN IV) OPTIMAL PCI study evaluating OCT-guided stent implantation vs stenting using angiography alone in 2487 patients from 18 countries at 80 sites globally, incl. in the US, India, Japan & EU
  • The study demonstrated improved stent expansion with a 7% increase in MSA over angiography guidance alone among patients undergoing percutaneous coronary interventions (PCI), reduced risk of future blockages. OCT guidance led to a 64% reduction in ST rates, resulting in a significant difference over angiography. The results were presented at ESC 2023 & published in The NEJM
  • OCT-guided PCIS vs angiography was also associated with a 39% reduction in cardiac death; 24% in target vessel myocardial infarction & also associated with a lower risk of AEs related to safety

Ref: Abbott | Image: Abbott

Related News:- Abbott Receives the US FDA’s Clearance for Alinity H-Series Hematology System

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions